Unlocking the Potential of TRNA Splicing Endonuclease Complex as a Drug Target or Biomarker

Target Name: tRNA splicing endonuclease complex

NCBI ID: P31059

tRNA splicing endonuclease complex

Other Name(s): None

Unlocking the Potential of TRNA Splicing Endonuclease Complex as a Drug Target or Biomarker

Introduction

The tRNA spliceosome complex is a crucial regulator of gene expression in eukaryotic cells. It plays a vital role in ensuring the accurate assembly of RNA molecules during the process of gene transcription. The tRNA spliceosome complex is composed of several subunits, including the tRNA splicing endonuclease (TEN) complex. This enzyme functions at the critical step of the splicing process, where it removed the non-coding end of the tRNA molecule and created a double-stranded RNA molecule that could be accurately spliced 鈥嬧?媔nto the final RNA product.

Recent studies have identified TEN as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is due to the unique mechanism of TEN's action and its potential to modulate the expression levels of various genes. In this article, we will delve into the biology of TEN and its potential as a drug target or biomarker.

The tRNA Spliceosome Complex

The tRNA spliceosome complex is a complex protein machinery that is responsible for regulating the splicing of RNA molecules into functional RNA products. It consists of several subunits, including TEN, which is the most well-studied subunit.

TEN is a nucleotide-binding enzyme that uses ATPase activity to recruit tRNA to its active site. tRNA exists in a client-server model, where the tRNA provides a binding site for the enzyme to recognize and initiate the splicing process. Once the tRNA is recruited to the active site, TEN uses its ATPase activity to activate the enzyme and begin the splicing process.

The tRNA spliceosome complex has a well-defined structure, with multiple distinct subunits that contribute to its function. The core of the complex contains the TEN enzyme, which is responsible for the essential step of the splicing process. The complex also contains a protein called TAS100, which is involved in the regulation of TEN's activity.

In addition to TAS100, the tRNA spliceosome complex contains several other proteins that help to ensure the proper functioning of the complex. These include the protein Sle1, which is involved in the regulation of TAS100 activity, as well as the protein Swi6, which is involved in the formation of the active site on the tRNA.

Potential Drug Targets or Biomarkers

Recent studies have identified TEN as a potential drug target or biomarker for various diseases. This is due to the unique mechanism of TEN's action and its potential to modulate the expression levels of various genes. In this section, we will discuss the potential drug targets or biomarkers for TEN.

1.Cancer

TEN has been shown to play a critical role in the regulation of gene expression in cancer cells. Studies have shown that TEN activity is highly upregulated in cancer cells, which suggests that it may be a potential drug target or biomarker for cancer.

One of the main mechanisms through which TEN may contribute to cancer development is its role in the regulation of microRNA (miRNA) levels. miRNA are small non-coding RNAs that play a critical role in post-transcriptional gene regulation. TEN has been shown to help regulate the levels of miRNA in cancer cells, which may contribute to its potential as a cancer drug target.

2. Neurodegenerative Diseases

TEN has also been shown to be involved in the regulation of protein levels in neurodegenerative diseases. These conditions include Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Studies have shown that TEN is involved in

Protein Name: TRNA Splicing Endonuclease Complex

The "tRNA splicing endonuclease complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about tRNA splicing endonuclease complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets